Major Finding: In patients on the highest dose of phentermine plus controlled-release topiramate, systolic BP reductions were significantly lower than with placebo: 3.4 mm Hg after 28 weeks in EQUATE, 3.8 mm Hg after 56 weeks in EQUIP, and 3.2 mm Hg after 56 weeks in CONQUER. (Source: Clinical Endocrinology News)
SAN DIEGO (MedPage Today) — A combination of phentermine and topiramate (Qnexa) appears to induce weight loss and a decrease in metabolic risk parameters for cardiovascular disease in obese patients, researchers reported here. (Source: MedPage Today Endocrinology)
MedWorm Message: Register for MedMatcha, MedWorm’s m edical advertising network, and receive $5 free advertising.
Major Finding: In patients on the highest dose of phentermine plus controlled-release topiramate, systolic blood pressure reductions were significantly lower than with placebo: 3.4 mm Hg after 28 weeks in EQUATE, 3.8 mm Hg after 56 weeks in EQUIP, and 3.2 mm Hg after 56 weeks in CONQUER. (Source: Family Practice News)
Major Finding: In patients on the highest dose of phentermine plus controlled-release topiramate, systolic blood pressure reductions were significantly lower than with placebo: 3.4 mm Hg after 28 weeks in EQUATE, 3.8 mm Hg after 56 weeks in EQUIP, and 3.2 mm Hg after 56 weeks in CONQUER. (Source: Cardiology News)
The highest dose of an investigational weight-loss therapy, a combination of very low-dose phentermine and controlled-release topiramate, reduces body weight by around 10% after a year of treatment…
For complete story visit theheart.org. (Source: theHeart.org)
MedWorm Message: Register for MedMatcha, MedWorm’s medical advertising network, and receive $5 free adver tising.
The highest dose of an investigational weight-loss therapy, a combination of very low-dose phentermine and controlled-release topiramate, reduces body weight by around 10% after a year of treatment and has favorable effects on blood pressure, according to analyses presented at a late-breaking trial session. Heartwire (Source: Medscape Today Headlines)
The highest dose of an investigational weight-loss therapy, a combination of very low-dose phentermine and controlled-release topiramate, reduces body weight by around 10% after a year of treatment and has favorable effects on blood pressure, according to analyses presented at a late-breaking trial session. Heartwire (Source: Medscape Today Headlines)
VIENNA â An investigational combination of phentermine and topiramate produced significant reductions in both hemoglobin A1c and body weight at 1 year in a phase II study of 130 patients with type 2 diabetes. (Source: Clinical Endocrinology News)
MedWorm Message: Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news f eed – updated hourly from thousands of authoritative health and news sources.